PPCB ▲ +2.0% - Propanc Biopharma, Inc.
$PPCB - Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
07-OCT-2026 08:31 AM ET
Share this post
More filings for $PPCB
PPCB ▼ -3.6% - Propanc Biopharma, Inc.Oct 26, 2026PPCB ▼ -15.6% - Propanc Biopharma, Inc.Oct 22, 2026PPCB ▼ -6.3% - Propanc Biopharma, Inc.Oct 22, 2026PPCB ▲ +5.9% - Propanc Biopharma, Inc.Oct 16, 2026PPCB ▲ +2.4% - Propanc Biopharma, Inc.Oct 14, 2026PPCB ▲ +7.9% - Propanc Biopharma, Inc.Sep 22, 2026
View full $PPCB filing history →💬 Comments
Loading comments…
Leave a comment